MOLOGEN AG: Good tolerance of the colorectal cancer medication MGN1703 in phase II/III study data will be presented at the symposium of ASCO in
Leading oncologists from throughout the world will come together on these days for the Gastrointestinal Cancers Symposium in
According to the statements of the researchers from MOLOGEN AG, the clinical study for MGN1703, for which the interim evaluation is expected in mid-year, has shown very good tolerance up until now. This is worth noting, because for this current study phase the highest dosage from the previous phase 1b was selected and continued. The applied dosage is approx. 5-10x higher than the dosage which has been used up to now by competitors in clinical studies. The dSLIM® DNAmolecule that was developed and patented by MOLOGEN is extremely low on side effects thanks to its unique structure, making this dosage possible.
Dr. Matthias Schroff, scientist and chairman of the board of MOLOGEN AG comments: "We are pleased that our colorectal cancer medication is being well tolerated during the current study. This encourages us in our efforts to offer future patients a cancer medication without significant side effects.“
The cancer medication MGN1703 is currently being investigated in the course of a phase II/III clinical study that is relevant for the approval in the treatment of metastasized colorectal cancer. The goal of the study is to significantly prevent the progression of the cancer significantly longer than has been possible with the treatment methods up to now. The study is currently being conducted at various study centers in
Product information and study centers
The study is recorded on all relevant Internet portals. To overview see website:
A study hotline at MOLOGEN AG for MGN1703 provides information individually and in strict confidence in accordance with medical discretion to interested doctors and patients on: +49 (0)800 646 1703
About MOLOGEN AG
MOLOGEN AG, a German bio-pharmaceutical company based in
Stock in MOLOGEN AG is listed in the Prime Standard of the German stock exchange
(ISIN DE 0006637200).
BIO Deutschland e.V. | DECHEMA - Gesellschaft für Chemische Technik und Biotechnologie e.V. | Deutsche Industrievereinigung Biotechnologie (DIB) | Stifterverband für die Deutsche Wissenschaft e.V. | Vereinigung deutscher Biotechnologie-Unternehmen (VBU) | Verband Forschender Arzneimittelhersteller e.V. (VFA) | Verband der Chemischen Industrie e.V. (VCI)
MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
Prof. Peter W. Hübner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 13
External Investor Relations
Kirchhoff Consult AG
Janina Wismar M.A.
Tel: +49 - 40 - 60 91 86 - 50
Fax: +49 - 40 - 60 91 86 - 16
Risk notice regarding forward-looking statements
Certain statements in this report contain forward-looking expressions or corresponding expressions with negation or deviating versions thereof or comparable terminology, these are designated as forward-looking statements. In addition, all information given here that relates to planned or future results from business sectors, financial figures, developments of the financial situation or other financial figures or statistical statements, contain such forward-looking statements. The company advises potential investors to not rely on these forward-looking statements as a prediction of actual future events. The company is not obliged to update these forward-looking statements that only reflect the situation on the day of publication, and rejects any liability therefor.